Reprogramming Energy Homeostasis in Overweight Individuals Via Exercise, Cognitive, and Social Training
Launched by BAMBINO GESÙ HOSPITAL AND RESEARCH INSTITUTE · Apr 9, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The RESILIENT project is a clinical trial aimed at understanding how to improve the body's response to a hormone called leptin in individuals who are overweight or obese, including both children and adults. Leptin helps control hunger and energy balance, but some people can become resistant to its effects. This study will explore whether combining Cognitive Training (which focuses on thinking skills) and Social Training (which emphasizes social interactions) can enhance leptin sensitivity more effectively than a standard health behavior program that includes diet and exercise. Participants will be involved in an 8-week program followed by a 12-week period without interventions.
To join the study, individuals must be aged between 21 and 40, have a condition of overweight or obesity, and have a minimum IQ of 85. Those with certain types of genetic obesity, mobility issues, systemic diseases, or who are currently on medication for chronic conditions will not be eligible. Throughout the trial, participants will undergo various assessments to measure how effective these interventions are, which may help lead to better long-term treatments for obesity and its related challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • a condition of overweight or obesity
- • Intelligence Quotient (IQ) ≥ 85
- Exclusion Criteria:
- • genetic or syndromic obesity;
- • reduced mobility;
- • systemic diseases;
- • ongoing pharmacological treatment for chronic conditions.
About Bambino Gesù Hospital And Research Institute
Bambino Gesù Hospital and Research Institute, located in Rome, Italy, is a leading pediatric healthcare facility renowned for its commitment to advancing child health through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institute focuses on developing cutting-edge therapies and interventions for various pediatric conditions, underpinned by a multidisciplinary approach that integrates clinical practice, research, and education. With a strong emphasis on patient-centered care, Bambino Gesù fosters collaboration with international research networks and regulatory bodies to ensure the highest standards of safety and efficacy in its trials, ultimately striving to improve health outcomes for children globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Rome, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported